Physician profile
Douglas W Kingma
NPI 1003871815
$35,168.81
in general payments reported to CMS, 2019-2025
17 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Hematology (Pathology) provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $2,612 · 2021: $8,693 · 2022: $516 · 2023: $1,121 · 2024: $444 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474 · Travel and Lodging: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.20 |
| Travel and Lodging | $469.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nanostring Technologies, INC. | $16,878.16 | 2019 | |
| Helena Laboratories Corporation | $7,143.43 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $6,880.27 | 2019-2025 | Clonoseq |
| Blueprint Medicines Corporation | $1,750.50 | 2021 | |
| Amgen INC. | $1,087.47 | 2019-2021 | |
| Veracyte, INC. | $664.05 | 2021 | |
| Jazz Pharmaceuticals INC. | $420.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $96.65 | 2019 | |
| Merck Sharp & Dohme LLC | $61.38 | 2019-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $51.65 | 2019-2023 | |
| Biocartis US, INC | $28.93 | 2019 | |
| Celgene Corporation | $26.75 | 2020 | |
| Abbott Laboratories | $23.98 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $17.44 | 2022 | |
| Pfizer INC. | $13.32 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $12.52 | 2019 | |
| Foundation Medicine, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Kingma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.